A Phase 1, First-in-Human, Dose Escalation and Expansion, Multicenter Study of XMT-2056 in Participants With Advanced/Recurrent Solid Tumors That Express HER2
This study tested a new experimental medicine called XMT-2056 for people with advanced cancers that produce a protein called HER2. The goal was to see if this medicine could target cancer cells directly while also helping the body's immune system fight the disease.
This study was open to people with advanced breast, stomach, lung, or colon cancer where standard treatments haven't worked or aren't an option. Participants needed to have a tumor that tests positive for the HER2 protein and be physically active enough to participate.
Patients received the experimental medication and underwent regular medical imaging, like CT or MRI scans, to see how the tumor responded. They were also required to provide a sample of their tumor tissue for testing throughout the study.
The study took place at research centers in Los Angeles and Stanford, California. Please note that this specific study has been terminated, meaning it is no longer recruiting or active.
- 1The study focused on cancers that have high levels of the HER2 protein.
- 2Researchers were looking at how safe and effective this new drug is for patients.
- 3This study has been officially terminated and is no longer accepting new patients.
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.